Send to a Friend Share

Shire (SHPGY) Grabs U.S. Rights to Resolor

January 10, 2012 7:04 AM EST
SHPGY Hot Sheet
Overall Analyst Rating:
    NEUTRAL (= Flat)
Shire plc (Nasdaq: SHPGY), has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V. Terms of the agreement have not been disclosed.

Resolor, a prokinetic, is part of Shire's gastrointestinal (GI) portfolio in Europe and is approved for use in 33 countries for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. Resolor is currently available in Germany, Ireland, Belgium, France, Greece and the United Kingdom, and will be commercially available in Italy in mid-January 2012. Additional launches throughout Europe are planned for 2012.

Under the terms of the agreement, the US rights to the Resolor trademark will be transferred to Shire.


Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In


Related Categories

FDA, Mergers and Acquisitions

Add Your Comment





Follow StreetInsider.com On Twitter